Anavex completes AD drug Phase 1 SAD study

The placebo-controlled, randomized study was designed to assess drug’s safety, tolerability along with pharmacokinetic parameters.

In the Phase 1 SAD study, the maximum tolerated single dose was defined per protocol as 55-60 mg.

The trial enrolled healthy male volunteers between the ages of 18 and 55 and who received s SAD’s over the course of the trial.

The results demonstrated that Anavex 2-73 was well tolerated below the 55-60 mg dose with only mild adverse events in some volunteers.

Anavex executive director George Tidmarsh said with the successful completion of this trial, they will immediately begin a multiple ascending dose trial.